Mass Spectrometry Derived Protein Biomarkers of Atherosclerotic Cardiovascular Disease Risk
This technology includes a combination of protein biomarkers and clinical risk factors to be used as an In Vitro Diagnostic Multivariate Index Assay (IVDMIA) that can improve the identification of individuals at high risk for atherosclerotic cardiovascular disease (ASCVD) and myocardial infarction (MI). Incorporation of novel protein biomarkers of ASCVD risk into risk assessment algorithms may improve their ability to identify individuals at high risk for ASCVD. We conducted mass spectrometry (iTRAQ) profiling of 861 circulating plasma proteins in 135 MI cases from the Framingham Heart Study (FHS), and identified panels of protein biomarkers that independently predicted the occurrence of new onset MI/ASCVD above and beyond established risk factors. The IVDMIA invention described combines the values of multiple variables using an interpretation function to yield a single, patient-specific result, that is intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment or prevention of disease.
- Ability to identify many high-risk individuals early in the course of subclinical disease progression
- These protein biomarkers can be measured reliably and reproducibly, non-invasively through blood